Single‐Cell Resolution Mapping of Osteoarthritis‐Associated Chondrocyte Dynamics Using a High‐Density CMOS MEA Platform
Advanced Healthcare Materials · 2026-11 · 15 (42)
DOI: 10.1002/adhm.202504115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 14.10.2026. Verfasst von Neha Deshpande und 9 weiteren Autor:innen. Beteiligte Einrichtung: imec, Leuven, Belgium. Hauptthemen laut MEDLINE: Chondrocytes, Osteoarthritis, Single-Cell Analysis. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: imec's Tenure Track program, DFG, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Fibrosis is a major cause of chronic tissue dysfunction and contributes substantially to morbidity and mortality worldwide. Osteoarthritis (OA), affecting over 590 million people, is a prevalent fibrotic joint disease for which disease‐modifying therapies remain lacking, partly because disease progression remains incompletely understood. As human‐relevant in vitro models, including organ‐on‐chip and microphysiological systems, become increasingly important, non‐invasive technologies capable of continuous cellular monitoring are urgently needed. Here, we implement high‐density complementary metal‐oxide‐semiconductor (CMOS) multielectrode array (MEA)‐based impedance profiling as a label‐free platform for longitudinal assessment of OA‐relevant chondrocyte remodeling. Human primary chondrocytes cultured on CMOS‐MEA chips exhibited impedance increases that correlated with electrode occupancy and extracellular matrix (ECM) deposition. Spatial impedance mapping enabled visualization of injury‐response dynamics, while oxidative stress induced progressive impedance decline accompanied by apoptosis, morphological remodeling, and chondrocyte dedifferentiation, evidenced by reduced collagen II and SOX9 expression and increased collagen I expression. In contrast, osteogenic de‐differentiation produced increased impedance associated with ECM remodeling and matrix mineralization. Together, these findings support high‐density CMOS‐MEA impedance profiling as a non‐invasive approach for monitoring cellular remodeling and provide a foundation for future integration of spatially resolved impedance sensing into advanced microphysiological systems for OA and other fibrotic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- imec, Leuven, Belgium.
- Department of Physics and Astronomy, KU Leuven, Leuven, Belgium.
- BIH Center for Regenerative Therapies, Berlin Institute of Health at Charité - Universitätsmedizin, Berlin, Germany.
- Julius Wolff Institute, Berlin Institute of Health at Charité - Universitätsmedizin, Berlin, Germany.
ORCID-Profile: Neha Deshpande, Pauline Coquart, Dennis Lambrechts, Johanna Bolander
Förderung
- imec's Tenure Track program
- DFG
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Deshpande, N., Coquart, P., Theuns, B., Cremery, S., Iii, J. R. V. G., Verplanken, J., Lambrechts, D., Braeken, D., Lagae, L., & Bolander, J. (2026). Single‐Cell Resolution Mapping of Osteoarthritis‐Associated Chondrocyte Dynamics Using a High‐Density CMOS MEA Platform. Advanced Healthcare Materials, 15(42). https://doi.org/10.1002/adhm.202504115
Vancouver
Deshpande N, Coquart P, Theuns B, Cremery S, Iii JRVG, Verplanken J, et al. Single‐Cell Resolution Mapping of Osteoarthritis‐Associated Chondrocyte Dynamics Using a High‐Density CMOS MEA Platform. Advanced Healthcare Materials. 2026;15(42). doi:10.1002/adhm.202504115
BibTeX
@article{Deshpande2026,
author = {Deshpande, Neha and Coquart, Pauline and Theuns, Bram and Cremery, Susanne and Iii, Jaime Rodolfo V Garcia and Verplanken, Julien and Lambrechts, Dennis and Braeken, Dries and Lagae, Liesbet and Bolander, Johanna},
title = {Single‐Cell Resolution Mapping of Osteoarthritis‐Associated Chondrocyte Dynamics Using a High‐Density CMOS MEA Platform},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {42},
doi = {10.1002/adhm.202504115}
}
EUVIMED